Carfilzomib is an irreversible, epoxyketone proteasome inhibitor, whereas bortezomib is a reversible, boronic acid-based proteasome inhibitor. The randomised phase 3 ENDEAVOR study directly compared carfilzomib (56 mg/m²) plus dexamethasone with bortezomib (1·3 mg/m²) plus dexamethasone in patients with relapsed or refractory multiple myeloma who had received between one and three previous therapies. The first pre-specified interim analysis showed that patients in the carfilzomib group had higher rates of deeper responses, which translated into significantly longer progression-free survival than those who received bortezomib (median progression-free survival 18·7 months [95% CI 15·6–not estimable] vs 9·4 months [8·4–10·4], hazard ratio [HR] 0·53 [95% CI 0·44–0·65]; p<0·0001).

中文翻译：

---

卡非佐米与硼替佐米：不再是ENDEAVOR

卡非佐米是不可逆的环氧酮蛋白酶体抑制剂，而硼替佐米是可逆的基于硼酸的蛋白酶体抑制剂。ENDEAVOR 3期随机研究直接比较了卡非佐米（56 mg / m ²）加地塞米松与硼替佐米（1·3 mg / m ²）加地塞米松在复发或难治性多发性骨髓瘤患者中曾接受过一至三种治疗的患者的疗效。首次预先指定的中期分析表明，卡非佐米组的患者有更高的更深反应率，这意味着比接受硼替佐米的患者无进展生存期明显更长（中位无进展生存期为18·7个月[95％CI 15 ·6 –不可估计] vs9·4个月[8·4-10·4]，危险比[HR] 0·53 [95％CI 0·44-0·65]；p <0·0001）。